March 21, 2001
Irvine biopharmaceutical company NeoTherapeutics Inc. incurred a net loss of $11.5 million, or 88 cents a share, for the fourth quarter, down from a net loss of $12.2 million, or $1.47 a share, for the 1999 fourth quarter, which included a charge of $2.5 million for a legal settlement. For the year, the company posted a net loss of $46.4 million, or $4.37 a share, compared with a 1999 net loss of $26 million, or $3.68 a share. The development-stage company reported no revenue.
March 20, 2001 |
Investors swept up shares of NeoTherapeutics Inc. on Monday after the Irvine biopharmaceutical company announced a license agreement with Pfizer Inc. worth up to $12 million. NeoTherapeutics, which until now has not generated revenue, will receive an initial payment from Pfizer.
March 8, 2001
Shares of NeoTherapeutics Inc. surged 20% Wednesday on news that investor Peter Kellogg has a 6.6% stake in the Irvine biopharmaceutical company. A company spokesman said the stock's 84-cent gain to $4.97 a share was related to a recent filing with the Securities and Exchange Commission showing that Kellogg holds 880,000 shares. The shares, which trade on Nasdaq, still have lost about nearly 80% of their value over the last year.
February 8, 2001 |
NeoTherapeutics Inc.'s climbing stock moved up an additional 30% Wednesday, snapped up by investors after the company said it is planning a pivotal study of its drug compound for treating Alzheimer's disease. The Irvine biopharmaceutical company also said this week that a subsidiary received $7 million in new financing. The stock, which rose 15% on Tuesday and 14% on Monday, closed Wednesday at $4.16, up 97 cents a share in Nasdaq trading. A total of 1.
February 6, 2001 |
NeoTherapeutics Inc. is planning a pivotal study in developing its lead drug compound, Neotrofin, to combat Alzheimer's disease. The Irvine biopharmaceutical company said the study, set to start in April, will test whether a higher dose of Neotrofin counters Alzheimer's symptoms, particularly memory loss, over 12 weeks. The study would be completed by the end of the year, assuming no enrollment delays.
January 3, 2001 |
NeoTherapeutics Inc. filed a shelf registration statement with the Securities and Exchange Commission to issue up to $50 million of debt securities, stock, depositary shares or warrants. The Irvine biopharmaceutical company said Tuesday the filing allows it "speed and flexibility" when market conditions are attractive. A shelf filing lets the company register securities in advance and sell them from time to time as needed.